When was Crescent Biopharma founded?

Crescent Biopharma was founded in 2024.

Where is Crescent Biopharma located?

Crescent Biopharma is headquartered in Boston, United States.

How many employees does Crescent Biopharma have?

As of Jun 30, 2026, the latest employee count at Crescent Biopharma is 70.

Is Crescent Biopharma a funded company?

Crescent Biopharma is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Crescent Biopharma rank among its competitors?

Crescent Biopharma ranks 937th amongst 3250 active competitors, of which 1119 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Crescent Biopharma?

Crescent Biopharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Crescent Biopharma - 2026 Company Profile & Competitors

Crescent Biopharma is an acquired company based in Boston (United States), founded in 2024. It operates as a Developer of precision engineered molecules targeting solid tumors. The company has 3250 active competitors, including 1119 funded and 771 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.

Company Details

Developer of precision engineered molecules targeting solid tumors. It offers a lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody, CR-002 and CR-003, antibody-drug conjugates with topoisomerase inhibitor payloads for solid tumor treatments.

Website: crescentbiopharma.com
Email ID: *****@crescentbiopharma.com

Key Metrics

Founded Year

2024

Location

Boston, United States

Stage

Acquired

Ranked

937^th among 3250 active competitors

Employee Count

70 as on Jun 30, 2026

Investment & Acquisitions

GlycoMimetics

Similar Companies

BeiGene & 551 more

Exit Details

Acquired by GlycoMimetics (Oct 29, 2024)

View Crescent Biopharma's full profile

Crescent Biopharma got acquired by GlycoMimetics on Oct 29, 2024.

Click here to take a look at Crescent Biopharma's acquisition in detail

Crescent Biopharma has not raised any funding rounds yet.

Crescent Biopharma's employee count trend

Crescent Biopharma has 70 employees as of Jun 26. Here is Crescent Biopharma's employee count trend over the years:

Employee count trend for Crescent Biopharma

Uncover Crescent Biopharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Crescent Biopharma include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Crescent Biopharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
937th	Crescent Biopharma 2024, Boston (United States), Acquired	Developer of precision engineered molecules targeting solid tumors	-	-	43/100